Key Points
- Director Georges Gemayel sold 8,787 shares on March 6 at an average price of $53 (total $465,711) and had sold 10,000 shares on March 5 at $53.71, cutting his stake to 27,277 shares (a 24.37% decrease).
- SUPN trading and analyst view: Shares trade around $54.17 (12‑month range $29.16–$59.68) with a $3.12B market cap; analysts are mixed but the consensus is a "Hold" with an average price target of $62.17.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Georges Gemayel sold 8,787 shares of the business's stock in a transaction on Friday, March 6th. The stock was sold at an average price of $53.00, for a total transaction of $465,711.00. Following the completion of the sale, the director owned 27,277 shares in the company, valued at approximately $1,445,681. The trade was a 24.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Georges Gemayel also recently made the following trade(s):
- On Thursday, March 5th, Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $53.71, for a total value of $537,100.00.
Supernus Pharmaceuticals Trading Up 0.6%
Shares of SUPN stock opened at $54.17 on Tuesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68. The stock's 50-day moving average price is $51.05 and its 200-day moving average price is $48.90. The stock has a market capitalization of $3.12 billion, a price-to-earnings ratio of -79.66, a price-to-earnings-growth ratio of 1.67 and a beta of 0.70.
Analysts Set New Price Targets
SUPN has been the topic of a number of research reports. Stifel Nicolaus lifted their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a "hold" rating in a research note on Friday, December 19th. Zacks Research downgraded Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Thursday, January 29th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Sunday. Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Finally, Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $62.17.
View Our Latest Analysis on Supernus Pharmaceuticals
Institutional Investors Weigh In On Supernus Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the stock. State Street Corp raised its position in Supernus Pharmaceuticals by 1.4% during the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company's stock valued at $110,296,000 after purchasing an additional 31,668 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company's stock worth $73,215,000 after purchasing an additional 62,875 shares during the period. Loomis Sayles & Co. L P increased its position in shares of Supernus Pharmaceuticals by 12.7% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company's stock valued at $72,007,000 after purchasing an additional 162,905 shares during the last quarter. Stephens Investment Management Group LLC increased its position in shares of Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company's stock valued at $69,904,000 after purchasing an additional 61,120 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company's stock valued at $60,398,000 after buying an additional 490,835 shares during the period.
About Supernus Pharmaceuticals
(
Get Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
